Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Afinitor

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

The UK’s new five-year pricing agreement

Pharma has agreed to capped growth again - in exchange for uptake promises

- PMLiVE

NHS tech leader departs for digital GP service

Hands baton over to Health Innovation Network chief

- PMLiVE

Blackwood returns as new life sciences minister

Replaces James O’Shaughnessy at DHSC

- PMLiVE

NICE rejects Novartis migraine treatment Aimovig

A draft 'no' to first-in-class treatment, despite discount

- PMLiVE

NHS Long-term Plan welcomed – but warnings on staff and overpromising

New emphasis on prevention, integrated healthcare and digital services

- PMLiVE

Afinitor and Uptravi gain funding from NHS England

Rare disease treatments navigate tricky market access route

- PMLiVE

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Room for manoeuvre after initial rejection

- PMLiVE

NICE appraisal fees to be introduced despite opposition

Concessions made for small companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links